Long Focus Capital Management LLC Has $39.22 Million Holdings in BioNTech SE Sponsored ADR $BNTX

Long Focus Capital Management LLC raised its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 91.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 397,655 shares of the company’s stock after acquiring an additional 189,752 shares during the period. BioNTech comprises about 1.3% of Long Focus Capital Management LLC’s investment portfolio, making the stock its 18th largest holding. Long Focus Capital Management LLC’s holdings in BioNTech were worth $39,217,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Financial Consulate Inc. acquired a new stake in shares of BioNTech during the third quarter worth about $36,000. Huntington National Bank grew its position in shares of BioNTech by 1,266.7% in the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the period. Tower Research Capital LLC TRC grew its position in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC increased its stake in BioNTech by 40.8% during the 3rd quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after purchasing an additional 227 shares in the last quarter. Finally, Rakuten Securities Inc. raised its holdings in BioNTech by 188.1% during the 3rd quarter. Rakuten Securities Inc. now owns 1,043 shares of the company’s stock worth $103,000 after buying an additional 681 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

Shares of BNTX opened at $90.54 on Tuesday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The stock has a market capitalization of $21.73 billion, a P/E ratio of -17.28 and a beta of 1.51. The company has a 50 day moving average of $106.30 and a 200-day moving average of $102.46.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Jefferies Financial Group cut their price target on shares of BioNTech from $151.00 to $138.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. HC Wainwright restated a “buy” rating and set a $140.00 price objective on shares of BioNTech in a report on Thursday, December 11th. UBS Group raised shares of BioNTech to a “hold” rating in a research report on Thursday, December 4th. TD Cowen reduced their target price on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research note on Wednesday, March 11th. Finally, Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a report on Monday, February 2nd. Twelve research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.